Gilead Sciences Inc.GILD

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · gilead.com

Gilead Sciences, Inc. is an American biopharmaceutical company that researches, develops, and commercializes medicines in areas of unmet medical need, with a primary focus on antiviral treatments for HIV/AIDS, hepatitis B, hepatitis C, and COVID-19. The company's commercial portfolio includes leading drugs such as Biktarvy and Descovy for HIV and Veklury (remdesivir) for COVID-19, and has expanded into oncology and inflammatory diseases through acquisitions.

Key ratios

Operating cash flow growth

37.3%TTM

2025 -7.5%2024 35.3%2023 -11.8%

EPS growth

55.4%TTM

2025 1684.2%2024 -91.6%2023 23.6%

FCF / Sales

42.5%TTM

2025 32.1%2024 35.8%2023 27.4%

Net margin

-10.6%TTM

2025 28.9%2024 1.7%2023 20.9%

ROA

14.1%TTM

2025 12.5%2024 11.0%2023 9.3%

ROE

-20.7%TTM

2025 40.7%2024 2.3%2023 25.5%

Revenue growth

5.5%TTM

2025 2.4%2024 6.0%2023 -0.6%

Recent news

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention 2026-06-15 · Gilead Sciences Gilead Sciences Announces First Quarter Financial Results 2026-05-07 · Gilead Sciences

Track GILD in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer